Vanessa M McMahan1, Susan Kingston2, Alison Newman2, Joanne D Stekler3, Sara N Glick4, Caleb J Banta-Green5. 1. Department of Medicine, University of Washington, 325 9(th)Avenue, Seattle, WA, 98104, USA; Department of Health Services, School of Public Health, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, USA. Electronic address: vanessa.mcmahan@sfdph.org. 2. Alcohol and Drug Abuse Institute, University of Washington, 1107 NE 45th St, Suite 120, Seattle, WA, 98105, USA. 3. Department of Medicine, University of Washington, 325 9(th)Avenue, Seattle, WA, 98104, USA; Department of Global Health, University of Washington, 1510 San Juan Road, Seattle, WA, 98195, USA; Department of Epidemiology, University of Washington, 1959 NE Pacific St, Seattle, WA, USA. 4. Department of Medicine, University of Washington, 325 9(th)Avenue, Seattle, WA, 98104, USA; HIV/STD Program, Public Health - Seattle & King County, Seattle, WA, USA. 5. Department of Health Services, School of Public Health, University of Washington, 1959 NE Pacific St, Seattle, WA, 98195, USA; Alcohol and Drug Abuse Institute, University of Washington, 1107 NE 45th St, Suite 120, Seattle, WA, 98105, USA.
Abstract
BACKGROUND: Methamphetamine use is increasing, and opioid use remains elevated in the US. Understanding interest in reducing/stopping substance use among people who inject drugs (PWID), as well as types of help wanted, can inform interventions. METHODS: Data from the 2019 Washington State Syringe Exchange Survey were used in logistic regression analyses to assess if demographics, substance use, and concern about anxiety or depression were associated with interest in reducing/stopping substance use among people whose main drug was methamphetamine or opioids. Types of help wanted to reduce/stop use are reported. RESULTS: Of 583 participants included, 76 % reported opioids were their main drug, of whom 82 % were interested in reducing/stopping their opioid use. 24 % reported methamphetamine as their main drug, of whom 46 % were interested in reducing/stopping their methamphetamine use. Among those whose main drug was an opioid, female gender (AOR:2.19, p = .023) and concern about depression (AOR:3.04, p = .002) were associated with interest in reducing/stopping opioid use. Among participants whose main drug was methamphetamine, being in jail in the past year and having an infection likely related to injection (e.g., abscess) in the past year were associated with over twice the odds of interest in reducing/stopping methamphetamine use (AOR:2.14, p = .056 and 2.43, p = .052, respectively); however, these findings were not significant. Several types of help to reduce/stop use were endorsed. CONCLUSION: There were high, though differing, levels of interest in reducing/stopping opioid or methamphetamine use and in a range of support services. PWID should be asked about interest in reducing/stopping use and provided appropriate support.
BACKGROUND: Methamphetamine use is increasing, and opioid use remains elevated in the US. Understanding interest in reducing/stopping substance use among people who inject drugs (PWID), as well as types of help wanted, can inform interventions. METHODS: Data from the 2019 Washington State Syringe Exchange Survey were used in logistic regression analyses to assess if demographics, substance use, and concern about anxiety or depression were associated with interest in reducing/stopping substance use among people whose main drug was methamphetamine or opioids. Types of help wanted to reduce/stop use are reported. RESULTS: Of 583 participants included, 76 % reported opioids were their main drug, of whom 82 % were interested in reducing/stopping their opioid use. 24 % reported methamphetamine as their main drug, of whom 46 % were interested in reducing/stopping their methamphetamine use. Among those whose main drug was an opioid, female gender (AOR:2.19, p = .023) and concern about depression (AOR:3.04, p = .002) were associated with interest in reducing/stopping opioid use. Among participants whose main drug was methamphetamine, being in jail in the past year and having an infection likely related to injection (e.g., abscess) in the past year were associated with over twice the odds of interest in reducing/stopping methamphetamine use (AOR:2.14, p = .056 and 2.43, p = .052, respectively); however, these findings were not significant. Several types of help to reduce/stop use were endorsed. CONCLUSION: There were high, though differing, levels of interest in reducing/stopping opioid or methamphetamine use and in a range of support services. PWID should be asked about interest in reducing/stopping use and provided appropriate support.
Authors: Caleb J Banta-Green; Mandy D Owens; Jason R Williams; Jeanne M Sears; Anthony S Floyd; Wendy Williams-Gilbert; Susan Kingston Journal: Addict Sci Clin Pract Date: 2022-07-07
Authors: Christopher M Jones; Debra Houry; Beth Han; Grant Baldwin; Alana Vivolo-Kantor; Wilson M Compton Journal: Ann N Y Acad Sci Date: 2021-09-24 Impact factor: 6.499
Authors: Manal Mansoor; Ryan McNeil; Taylor Fleming; Allison Barker; Sheila Vakharia; Kimberly Sue; Andrew Ivsins Journal: Int J Drug Policy Date: 2022-01-31